These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 32615788)

  • 1. Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache.
    Navratilova E; Behravesh S; Oyarzo J; Dodick DW; Banerjee P; Porreca F
    Cephalalgia; 2020 Aug; 40(9):892-902. PubMed ID: 32615788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache.
    Rau JC; Navratilova E; Oyarzo J; Johnson KW; Aurora SK; Schwedt TJ; Dodick DW; Porreca F
    Cephalalgia; 2020 Aug; 40(9):903-912. PubMed ID: 32580575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.
    Kopruszinski CM; Navratilova E; Swiokla J; Dodick DW; Chessell IP; Porreca F
    Cephalalgia; 2021 Mar; 41(3):305-317. PubMed ID: 32985222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice.
    Navratilova E; Rau J; Oyarzo J; Tien J; Mackenzie K; Stratton J; Remeniuk B; Schwedt T; Anderson T; Dodick D; Porreca F
    Cephalalgia; 2019 Dec; 39(14):1762-1775. PubMed ID: 31550910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache.
    Nation KM; Dodick DW; Navratilova E; Porreca F
    Cephalalgia; 2019 Apr; 39(5):617-625. PubMed ID: 30286616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triptan-induced latent sensitization: a possible basis for medication overuse headache.
    De Felice M; Ossipov MH; Wang R; Lai J; Chichorro J; Meng I; Dodick DW; Vanderah TW; Dussor G; Porreca F
    Ann Neurol; 2010 Mar; 67(3):325-37. PubMed ID: 20373344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent administration of the nitric oxide donor, isosorbide dinitrate, induces a persistent cephalic cutaneous hypersensitivity: A model for migraine progression.
    Dallel R; Descheemaeker A; Luccarini P
    Cephalalgia; 2018 Apr; 38(4):776-785. PubMed ID: 28565942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoids induce latent sensitization in a preclinical model of medication overuse headache.
    Kopruszinski CM; Navratilova E; Vagnerova B; Swiokla J; Patwardhan A; Dodick D; Porreca F
    Cephalalgia; 2020 Jan; 40(1):68-78. PubMed ID: 31311288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents.
    Kopruszinski CM; Xie JY; Eyde NM; Remeniuk B; Walter S; Stratton J; Bigal M; Chichorro JG; Dodick D; Porreca F
    Cephalalgia; 2017 May; 37(6):560-570. PubMed ID: 27206958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prolactin-dependent sexually dimorphic mechanism of migraine chronification.
    Ikegami D; Navratilova E; Yue X; Moutal A; Kopruszinski CM; Khanna R; Patwardhan A; Dodick DW; Porreca F
    Cephalalgia; 2022 Mar; 42(3):197-208. PubMed ID: 34510920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache.
    Green AL; Gu P; De Felice M; Dodick D; Ossipov MH; Porreca F
    Cephalalgia; 2014 Jul; 34(8):594-604. PubMed ID: 24335852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans.
    Jakate A; Boinpally R; Butler M; Lu K; McGeeney D; Periclou A
    Headache; 2020 Jul; 60(7):1340-1350. PubMed ID: 32573795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers.
    De Felice M; Ossipov MH; Wang R; Dussor G; Lai J; Meng ID; Chichorro J; Andrews JS; Rakhit S; Maddaford S; Dodick D; Porreca F
    Brain; 2010 Aug; 133(Pt 8):2475-88. PubMed ID: 20627971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention.
    Xie JY; De Felice M; Kopruszinski CM; Eyde N; LaVigne J; Remeniuk B; Hernandez P; Yue X; Goshima N; Ossipov M; King T; Streicher JM; Navratilova E; Dodick D; Rosen H; Roberts E; Porreca F
    Cephalalgia; 2017 Jul; 37(8):780-794. PubMed ID: 28376659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nitric oxide donor, isosorbide dinitrate, induces a cephalic cutaneous hypersensitivity, associated with sensitization of the medullary dorsal horn.
    Flores Ramos JM; Devoize L; Descheemaeker A; Molat JL; Luccarini P; Dallel R
    Neuroscience; 2017 Mar; 344():157-166. PubMed ID: 28057535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine.
    Kopruszinski CM; Thornton P; Arnold J; Newton P; Lowne D; Navratilova E; Swiokla J; Dodick DW; Dobson C; Gurrell I; Chessell IP; Porreca F
    Cephalalgia; 2020 Dec; 40(14):1535-1550. PubMed ID: 33131305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II.
    Dodick DW; Lipton RB; Ailani J; Halker Singh RB; Shewale AR; Zhao S; Trugman JM; Yu SY; Viswanathan HN
    Headache; 2020 Apr; 60(4):686-700. PubMed ID: 32073660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors.
    Jakubowski M; Levy D; Goor-Aryeh I; Collins B; Bajwa Z; Burstein R
    Headache; 2005; 45(7):850-61. PubMed ID: 15985101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study.
    Schwedt TJ; Alam A; Reed ML; Fanning KM; Munjal S; Buse DC; Dodick DW; Lipton RB
    J Headache Pain; 2018 May; 19(1):38. PubMed ID: 29797100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of CGRP-dependent pain and headache related behaviours in a rat model of concussion: Implications for mechanisms of post-traumatic headache.
    Bree D; Levy D
    Cephalalgia; 2018 Feb; 38(2):246-258. PubMed ID: 27899434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.